This post was originally published on this site Fexapotide triflutate improves the sexual functioning of men with an enlarged prostate, according to combined results of four Phase 3 clinical trials. The therapy’s developer, Nymox Pharmaceutical, had previously reported that Fexapotide caused no sexual or other side effects, but improved sexual function is a new and important finding.…
This post was originally published on this site Naftopidil, a medication used to treat benign prostatic hyperplasia (BPH) outside the United States, lowers blood pressure in BPH men with hypertension while having no effect on those with normal blood pressure, a Korean study found. The drug, an alpha-blocker, also improved prostate symptoms and quality of…
This post was originally published on this site Patients being treated with a combination 5-alpha reductase inhibitor (5ARIs) and an alpha blocker may switch to 5ARIs alone with no worsening of lower urinary tract symptoms (LUTS), a new study says. But in overweight patients, the withdrawal must be carefully monitored. These findings, in the study “Effects of…
This post was originally published on this site The rate of obesity increased faster among cancer survivors than the general population in the 14 years between 1997 and 2014, according to a study published in the Journal of Clinical Oncology. “We knew that obesity rates have been increasing in the general population, but we did…
This post was originally published on this site Juno Therapeutics and privately held biotech Eureka Therapeutics have entered into an immunotherapy development partnership with Memorial Sloan Kettering Cancer Center (MSK) of New York City. The exclusive license agreement is for joint development of a novel fully-human binding domain targeting B-cell maturation antigen (BCMA), and binding domains against two…
This post was originally published on this site The Multiple Myeloma Research Foundation (MMRF) and the University of Michigan have partnered to provide multiple myeloma patients and their doctors access to personal genomic information which can help guide treatments based on genomic alterations. Over the course of the two-year Molecular Profiling Initiative (MPI), the two institutions…
This post was originally published on this site In a video posted on Healio’s Hematology-Oncology page, Dr. Ola Landgren, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York City, speaks about new treatments and ongoing discoveries in the field of multiple myeloma. A lot is taking place, quickly, according to Landgren. “I…
This post was originally published on this site Recently, researchers in England released preliminary findings from a twin study that suggests the development of nuclear cataracts may be significantly delayed if the patient eats a diet rich in vitamin C. The study, “Genetic and Dietary Factors Influencing the Progression of Nuclear Cataract,” was published in…
This post was originally published on this site Researchers have found that rural areas in Germany have lower standards of care offered to cataract patients compared to treatment received by those living in urban areas. “In this part of Germany there are only a few cities surrounded by countryside, where medical services are structurally weaker,” Tim Herbst,…
This post was originally published on this site Myopia, which affects the muscles used to focus the lens of the eye, appears to have clinical implications for “accommodating,” or focusing, intraocular lens (IOLs) implants that help the eye adapt to different visual distances, according to a study in the journal Optometry and Vision Science, titled “The Effect of Age,…
